Small Molecules and Antibodies for Zika Therapy

Xuping Xie, Jing Zou, Chao Shan, Pei-Yong Shi

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Zika virus (ZIKV) infection during pregnancy can cause devastating congenital abnormities or fetal demise. Zika virus infection could also cause Guillain-Barré syndrome in adults. Mosquito control, vaccine, and therapeutics are 3 potential, effective means to prevent ZIKV infection. Here we review the current status of ZIKV drug discovery. Both small molecule inhibitors and therapeutic antibodies have been identified, some of which have shown promising efficacy in mouse models. Most inhibitors were identified through screening US Food and Drug Administration-approved drugs and clinical trial compounds; however, none of them were potent enough to justify a ZIKV clinical trial. Such a repurposing approach has also been pursued for dengue therapy, with several compounds tested in clinical trials showing no clinical benefits. Because pregnant women are the main target population for ZIKV treatment, therapeutic candidates could be developed through a 2-stage path. The first stage should demonstrate safety and efficacy in nonpregnant patients. Once efficacy has been demonstrated in nonpregnant patients, the candidates should be rapidly advanced to stage 2 for safety and efficacy evaluation in pregnant patients. The 2-stage developmental path is supported by previous results from trials with other viral infections that showed that treatment of pregnant women with antiviral drugs or hyperimmunoglobulins significantly reduced congenital abnormalities in neonates.

Original languageEnglish (US)
Pages (from-to)S945-S950
JournalJournal of Infectious Diseases
Volume216
DOIs
StatePublished - Jan 1 2017

Fingerprint

Antibodies
Clinical Trials
Pregnant Women
Therapeutics
Mosquito Control
Safety
Fetal Death
Dengue
Health Services Needs and Demand
Virus Diseases
Drug Discovery
United States Food and Drug Administration
Antiviral Agents
Vaccines
Newborn Infant
Pregnancy
Pharmaceutical Preparations
Zika Virus Infection
Zika Virus

Keywords

  • drug discovery
  • therapeutics
  • Zika

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Small Molecules and Antibodies for Zika Therapy. / Xie, Xuping; Zou, Jing; Shan, Chao; Shi, Pei-Yong.

In: Journal of Infectious Diseases, Vol. 216, 01.01.2017, p. S945-S950.

Research output: Contribution to journalReview article

Xie, Xuping ; Zou, Jing ; Shan, Chao ; Shi, Pei-Yong. / Small Molecules and Antibodies for Zika Therapy. In: Journal of Infectious Diseases. 2017 ; Vol. 216. pp. S945-S950.
@article{1aa4a37c8acc427d96ec52bbe7cb2d1e,
title = "Small Molecules and Antibodies for Zika Therapy",
abstract = "Zika virus (ZIKV) infection during pregnancy can cause devastating congenital abnormities or fetal demise. Zika virus infection could also cause Guillain-Barr{\'e} syndrome in adults. Mosquito control, vaccine, and therapeutics are 3 potential, effective means to prevent ZIKV infection. Here we review the current status of ZIKV drug discovery. Both small molecule inhibitors and therapeutic antibodies have been identified, some of which have shown promising efficacy in mouse models. Most inhibitors were identified through screening US Food and Drug Administration-approved drugs and clinical trial compounds; however, none of them were potent enough to justify a ZIKV clinical trial. Such a repurposing approach has also been pursued for dengue therapy, with several compounds tested in clinical trials showing no clinical benefits. Because pregnant women are the main target population for ZIKV treatment, therapeutic candidates could be developed through a 2-stage path. The first stage should demonstrate safety and efficacy in nonpregnant patients. Once efficacy has been demonstrated in nonpregnant patients, the candidates should be rapidly advanced to stage 2 for safety and efficacy evaluation in pregnant patients. The 2-stage developmental path is supported by previous results from trials with other viral infections that showed that treatment of pregnant women with antiviral drugs or hyperimmunoglobulins significantly reduced congenital abnormalities in neonates.",
keywords = "drug discovery, therapeutics, Zika",
author = "Xuping Xie and Jing Zou and Chao Shan and Pei-Yong Shi",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/infdis/jix406",
language = "English (US)",
volume = "216",
pages = "S945--S950",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Small Molecules and Antibodies for Zika Therapy

AU - Xie, Xuping

AU - Zou, Jing

AU - Shan, Chao

AU - Shi, Pei-Yong

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Zika virus (ZIKV) infection during pregnancy can cause devastating congenital abnormities or fetal demise. Zika virus infection could also cause Guillain-Barré syndrome in adults. Mosquito control, vaccine, and therapeutics are 3 potential, effective means to prevent ZIKV infection. Here we review the current status of ZIKV drug discovery. Both small molecule inhibitors and therapeutic antibodies have been identified, some of which have shown promising efficacy in mouse models. Most inhibitors were identified through screening US Food and Drug Administration-approved drugs and clinical trial compounds; however, none of them were potent enough to justify a ZIKV clinical trial. Such a repurposing approach has also been pursued for dengue therapy, with several compounds tested in clinical trials showing no clinical benefits. Because pregnant women are the main target population for ZIKV treatment, therapeutic candidates could be developed through a 2-stage path. The first stage should demonstrate safety and efficacy in nonpregnant patients. Once efficacy has been demonstrated in nonpregnant patients, the candidates should be rapidly advanced to stage 2 for safety and efficacy evaluation in pregnant patients. The 2-stage developmental path is supported by previous results from trials with other viral infections that showed that treatment of pregnant women with antiviral drugs or hyperimmunoglobulins significantly reduced congenital abnormalities in neonates.

AB - Zika virus (ZIKV) infection during pregnancy can cause devastating congenital abnormities or fetal demise. Zika virus infection could also cause Guillain-Barré syndrome in adults. Mosquito control, vaccine, and therapeutics are 3 potential, effective means to prevent ZIKV infection. Here we review the current status of ZIKV drug discovery. Both small molecule inhibitors and therapeutic antibodies have been identified, some of which have shown promising efficacy in mouse models. Most inhibitors were identified through screening US Food and Drug Administration-approved drugs and clinical trial compounds; however, none of them were potent enough to justify a ZIKV clinical trial. Such a repurposing approach has also been pursued for dengue therapy, with several compounds tested in clinical trials showing no clinical benefits. Because pregnant women are the main target population for ZIKV treatment, therapeutic candidates could be developed through a 2-stage path. The first stage should demonstrate safety and efficacy in nonpregnant patients. Once efficacy has been demonstrated in nonpregnant patients, the candidates should be rapidly advanced to stage 2 for safety and efficacy evaluation in pregnant patients. The 2-stage developmental path is supported by previous results from trials with other viral infections that showed that treatment of pregnant women with antiviral drugs or hyperimmunoglobulins significantly reduced congenital abnormalities in neonates.

KW - drug discovery

KW - therapeutics

KW - Zika

UR - http://www.scopus.com/inward/record.url?scp=85040240733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040240733&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix406

DO - 10.1093/infdis/jix406

M3 - Review article

VL - 216

SP - S945-S950

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -